These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16810529)

  • 1. Instant gratification must wait.
    Divgi C
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):979-80. PubMed ID: 16810529
    [No Abstract]   [Full Text] [Related]  

  • 2. [18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
    De Giorgi U; Amadori D
    J Clin Oncol; 2010 May; 28(15):e236-7; author reply e238. PubMed ID: 20177016
    [No Abstract]   [Full Text] [Related]  

  • 3. [Monitorized use of 18FDG positron emission tomography].
    Rodríguez Garrido M; Asensio del Barrio C
    Rev Esp Med Nucl; 2006; 25(3):217-20. PubMed ID: 16871675
    [No Abstract]   [Full Text] [Related]  

  • 4. Positron emission tomography (PET) in the evaluation of patients with cancer.
    Godwin HA; Zuger JH
    Trans Am Clin Climatol Assoc; 1999; 110():181-94. PubMed ID: 10344016
    [No Abstract]   [Full Text] [Related]  

  • 5. SUV: from silly useless value to smart uptake value.
    Visser EP; Boerman OC; Oyen WJ
    J Nucl Med; 2010 Feb; 51(2):173-5. PubMed ID: 20080897
    [No Abstract]   [Full Text] [Related]  

  • 6. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.
    Schelbert HR; Hoh CK; Royal HD; Brown M; Dahlbom MN; Dehdashti F; Wahl RL
    J Nucl Med; 1998 Jul; 39(7):1302-5. PubMed ID: 9669415
    [No Abstract]   [Full Text] [Related]  

  • 7. Proliferation imaging to measure early cancer response to targeted therapy.
    Mankoff DA; Eary JF
    Clin Cancer Res; 2008 Nov; 14(22):7159-60. PubMed ID: 19010830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
    Wells P; West C; Jones T; Harris A; Price P
    Biochim Biophys Acta; 2004 Dec; 1705(2):91-102. PubMed ID: 15588764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond FDG: Many Molecular Imaging Agents Are in Development.
    Brower V
    J Natl Cancer Inst; 2011 Jan; 103(1):13-5. PubMed ID: 21169540
    [No Abstract]   [Full Text] [Related]  

  • 10. Positron-emitting radiopharmaceuticals: how safe are they?
    Silberstein EB
    Cancer Biother Radiopharm; 2001 Feb; 16(1):13-5. PubMed ID: 11279793
    [No Abstract]   [Full Text] [Related]  

  • 11. [Technical Approaches for Quantitative Treatment Responses Using 18F-FDG PET].
    Miwa K; Miyaji N; Umeda T; Murata T; Wagatsuma K; Sasaki M
    Igaku Butsuri; 2015; 35(1):30-8. PubMed ID: 26753394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of PET for monitoring cancer therapy and for predicting outcome.
    Weber WA
    J Nucl Med; 2005 Jun; 46(6):983-95. PubMed ID: 15937310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality control of PET imaging: from study to diagnosis].
    Daisaki H
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2012; 68(7):916-25. PubMed ID: 22821167
    [No Abstract]   [Full Text] [Related]  

  • 15. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations.
    Gordon BA; Flanagan FL; Dehdashti F
    AJR Am J Roentgenol; 1997 Dec; 169(6):1675-80. PubMed ID: 9393189
    [No Abstract]   [Full Text] [Related]  

  • 16. [Oncology PET imaging].
    Inubushi M
    Igaku Butsuri; 2014; 34(1):3-9. PubMed ID: 25199271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry. Expanding the scope of fluorine tags for PET imaging.
    Zhu L; Ploessl K; Kung HF
    Science; 2013 Oct; 342(6157):429-30. PubMed ID: 24159034
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of positron-emission tomography in oncology].
    Strauss LG; Kabelitz D; Kremer B; Lode H; Meinertz T; Sauerbruch T; Sterry W
    Dtsch Med Wochenschr; 1996 Feb; 121(7):207-9. PubMed ID: 8681765
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncological applications of FDG PET imaging.
    Delbeke D
    J Nucl Med; 1999 Oct; 40(10):1706-15. PubMed ID: 10520713
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.
    Sanz-Viedma S; Torigian DA; Parsons M; Basu S; Alavi A
    Rev Esp Med Nucl; 2009; 28(3):159-66. PubMed ID: 19558958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.